JP2012526832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526832A5 JP2012526832A5 JP2012510964A JP2012510964A JP2012526832A5 JP 2012526832 A5 JP2012526832 A5 JP 2012526832A5 JP 2012510964 A JP2012510964 A JP 2012510964A JP 2012510964 A JP2012510964 A JP 2012510964A JP 2012526832 A5 JP2012526832 A5 JP 2012526832A5
- Authority
- JP
- Japan
- Prior art keywords
- transnorsertraline
- pharmaceutical composition
- serotonin receptor
- disorder
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 7
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000036651 mood Effects 0.000 claims 3
- XIGAHNVCEFUYOV-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC=CC=C1N1CCN(CCN(C(=O)C2CCCCC2)C=2N=CC=CC=2)CC1 XIGAHNVCEFUYOV-BTJKTKAUSA-N 0.000 claims 2
- NRPQELCNMADTOZ-OAQYLSRUSA-N 4-cyano-n-[(2r)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-n-pyridin-2-ylbenzamide Chemical compound C([C@@H](C)N1CCN(CC1)C=1C=2OCCOC=2C=CC=1)N(C=1N=CC=CC=1)C(=O)C1=CC=C(C#N)C=C1 NRPQELCNMADTOZ-OAQYLSRUSA-N 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical group C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims 2
- 229960002495 buspirone Drugs 0.000 claims 2
- SRPXSILJHWNFMK-MEDUHNTESA-N dasotraline Chemical group C1([C@@H]2CC[C@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-MEDUHNTESA-N 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- WVLHGCRWEHCIOT-UHFFFAOYSA-N eltoprazine Chemical compound C1CNCCN1C1=CC=CC2=C1OCCO2 WVLHGCRWEHCIOT-UHFFFAOYSA-N 0.000 claims 2
- 229950006047 eltoprazine Drugs 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 229950007396 lecozotan Drugs 0.000 claims 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical group CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 2
- 229960002508 pindolol Drugs 0.000 claims 2
- 208000012672 seasonal affective disease Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 claims 2
- 229950000505 tandospirone Drugs 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001457 vasomotor Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17799709P | 2009-05-13 | 2009-05-13 | |
| US61/177,997 | 2009-05-13 | ||
| PCT/US2010/034473 WO2010132521A1 (en) | 2009-05-13 | 2010-05-12 | Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015113773A Division JP2015180673A (ja) | 2009-05-13 | 2015-06-04 | トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012526832A JP2012526832A (ja) | 2012-11-01 |
| JP2012526832A5 true JP2012526832A5 (https=) | 2013-06-27 |
Family
ID=42306730
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510964A Pending JP2012526832A (ja) | 2009-05-13 | 2010-05-12 | トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用 |
| JP2015113773A Pending JP2015180673A (ja) | 2009-05-13 | 2015-06-04 | トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015113773A Pending JP2015180673A (ja) | 2009-05-13 | 2015-06-04 | トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120077818A1 (https=) |
| EP (1) | EP2429514A1 (https=) |
| JP (2) | JP2012526832A (https=) |
| CN (1) | CN102573823B (https=) |
| CA (1) | CA2759180A1 (https=) |
| WO (1) | WO2010132521A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| EP2455075B1 (en) | 2005-07-06 | 2018-06-20 | Sunovion Pharmaceuticals Inc. | Process for Preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine |
| WO2011064769A1 (en) * | 2009-11-24 | 2011-06-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and pharmaceutical compositions for the treatment of hot flashes |
| WO2011069032A2 (en) * | 2009-12-04 | 2011-06-09 | Sunovion Pharmaceuticals Inc. | Formulations, salts and polymorphs of transnorsertraline and uses thereof |
| JP6436024B2 (ja) | 2015-09-14 | 2018-12-12 | 住友電気工業株式会社 | 炭化珪素エピタキシャル基板の製造方法 |
| US20200405867A1 (en) * | 2018-01-19 | 2020-12-31 | Sunovion Pharmaceuticals Inc. | Oral dosage forms |
| WO2019182915A1 (en) * | 2018-03-19 | 2019-09-26 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of depression |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| WO2020092496A1 (en) * | 2018-10-31 | 2020-05-07 | Sunovion Pharmaceuticals Inc. | Methods of treating central nervous system disorders |
| WO2025049588A1 (en) * | 2023-08-29 | 2025-03-06 | The Trustees Of Indiana University | Novel treatments for optic neuropathies and glaucoma |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5810518A (ja) * | 1981-07-14 | 1983-01-21 | Kowa Yakuhin Kogyo Kk | アルコ−ル中毒または鎮静催眠薬中毒治療剤 |
| US4634703A (en) * | 1985-10-25 | 1987-01-06 | Bristol-Myers Company | Method for alleviation of panic disorders |
| US4687772A (en) * | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
| US4777173A (en) * | 1987-03-25 | 1988-10-11 | Bristol-Myers Company | Method for treatment of alcohol abuse |
| US5468749A (en) * | 1988-08-30 | 1995-11-21 | Gawin; Frank H. | Method for treatment of substance addiction |
| IL91451A0 (en) * | 1988-08-30 | 1990-04-29 | Bristol Myers Co | Pharmaceutical compositions comprising azapiron compounds and their use in the treatment of addiction |
| IL97054A (en) * | 1990-02-12 | 1995-10-31 | Bristol Meyers Squibb Co | Pharmaceutical preparations containing bospirone for the treatment of coma |
| JPH03246225A (ja) * | 1990-02-20 | 1991-11-01 | Bristol Myers Squibb Co | メランコリーうつ病の治療法 |
| JPH04327532A (ja) * | 1991-01-31 | 1992-11-17 | Bristol Myers Squibb Co | 活動過剰を伴う注意力欠乏疾患の治療に使用する医薬製剤 |
| US5330762A (en) * | 1992-02-27 | 1994-07-19 | Alza Corporation | Tandospiaine antidepressive therapy |
| US5858407A (en) * | 1992-02-27 | 1999-01-12 | Alza Corporation | Method for administering tandospirone |
| ATE192042T1 (de) * | 1995-08-16 | 2000-05-15 | Lilly Co Eli | Potenzierung von serotonin-wirkstoffresponz |
| EP0792649A1 (en) * | 1996-02-29 | 1997-09-03 | Eli Lilly And Company | Treatment of sleep disorders |
| EP0818198A1 (en) * | 1996-07-09 | 1998-01-14 | Lilly S.A. | Potentiation of drug response by increasing serotonin availability |
| US6500827B2 (en) * | 1998-05-08 | 2002-12-31 | Pharmacia & Upjohn Company | Drug combinations |
| PT1075264E (pt) * | 1998-05-08 | 2005-01-31 | Upjohn Co | Novas combinacoes farmacologicas de reboxetina e pindolol |
| JP2002020291A (ja) * | 2000-06-30 | 2002-01-23 | Sumitomo Pharmaceut Co Ltd | 認知機能障害の治療剤 |
| DE60229123D1 (de) * | 2001-02-20 | 2008-11-13 | Dinan Timothy Gerard | Behandlung von fibromyalgie mit pindolol |
| US20020183306A1 (en) * | 2001-05-30 | 2002-12-05 | Pfizer Inc. | Combination treatment for sleep disorders including sleep apnea |
| ATE424825T1 (de) * | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
| JP2003335678A (ja) * | 2002-05-17 | 2003-11-25 | Sumitomo Pharmaceut Co Ltd | 神経因性疼痛治療薬 |
| BRPI0314377B8 (pt) * | 2002-09-16 | 2021-05-25 | Sepracor Inc | composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto |
| AU2005283829A1 (en) * | 2004-09-17 | 2006-03-23 | Neurocure Ltd | Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder |
| US20080262071A1 (en) * | 2004-09-17 | 2008-10-23 | Timothy Dinan | Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder |
| EP2455075B1 (en) * | 2005-07-06 | 2018-06-20 | Sunovion Pharmaceuticals Inc. | Process for Preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine |
| TW200800198A (en) * | 2005-09-09 | 2008-01-01 | Wyeth Corp | Pharmaceutical dosage forms and compositions |
| EP2043745A2 (en) * | 2006-05-31 | 2009-04-08 | SEPRACOR Inc | Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide |
-
2010
- 2010-05-12 CN CN201080019852.5A patent/CN102573823B/zh not_active Expired - Fee Related
- 2010-05-12 US US13/320,246 patent/US20120077818A1/en not_active Abandoned
- 2010-05-12 WO PCT/US2010/034473 patent/WO2010132521A1/en not_active Ceased
- 2010-05-12 EP EP10719204A patent/EP2429514A1/en not_active Withdrawn
- 2010-05-12 CA CA2759180A patent/CA2759180A1/en not_active Abandoned
- 2010-05-12 JP JP2012510964A patent/JP2012526832A/ja active Pending
-
2015
- 2015-06-04 JP JP2015113773A patent/JP2015180673A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526832A5 (https=) | ||
| Yang et al. | Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression | |
| AR079542A1 (es) | Derivados de benzamida sustituidos, proceso para su preparacion y su uso en el tratamiento de enfermedades mediadas por taars. | |
| CU20150180A7 (es) | Piridin-2 que contienen il-4-derivados sustituidos de 1-diazino fenilo útiles como ligandos de dopamina | |
| JP2010529118A5 (https=) | ||
| JP2007516941A5 (https=) | ||
| Thomas et al. | The pharmacology of Tourette syndrome | |
| MX394941B (es) | Métodos y composiciones para el tratamiento de apnea del sueño | |
| CL2008001215A1 (es) | Compuestos derivados de heterociclos nitrogenados condensados; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, dislipidemia, obesidad y alzheimer. | |
| CL2008002864A1 (es) | Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros. | |
| ECSP12012098A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos | |
| NZ630260A (en) | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same | |
| WO2014120936A3 (en) | Treatments for depression and other diseases with a low dose agent | |
| JP2013525444A5 (https=) | ||
| JP2008524262A5 (https=) | ||
| JP2009541443A5 (https=) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| NZ582925A (en) | Use of bubropion hydrobromide for the prevention of seizures associated with bupropion administration | |
| JP2020503246A5 (https=) | ||
| EA201200975A1 (ru) | Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение | |
| WO2012138599A3 (en) | Hepatocyte growth factor mimics as therapeutic agents | |
| EA201590406A1 (ru) | Мочевинные и амидные производные аминоалкилпиперазинов и их применение | |
| CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
| CL2012002540A1 (es) | Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras. | |
| JP2008511569A5 (https=) |